• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/8/26 4:33:52 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    false 0000927066 0000927066 2026-06-04 2026-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): June 4, 2026

     

    DAVITA INC.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware 1-14106 51-0354549

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

    2000 16th Street

    Denver, CO

    80202
    (Address of Principal Executive Offices) (Zip Code)

     

    (720) 631-2100

    (Registrant’s telephone number, including area code)

     

    Not applicable

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

     Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading

    Symbol(s)

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value   DVA   New York Stock Exchange

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    ¨ Emerging growth company
    ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On June 8, 2026, DaVita Inc. (the “Company”) entered into a Ninth Amendment (the “Ninth Amendment”) to that certain Credit Agreement dated as of August 12, 2019 (as previously amended, restated, supplemented, or otherwise modified, and as further amended by the Ninth Amendment, the “Credit Agreement”), by and among the Company, its subsidiary guarantors, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and swingline lender (“JPMorgan”).

     

    The Ninth Amendment, among other things, provides for an incremental borrowing under the Company’s existing senior secured term loan “B” facility maturing in May 2031 (the “Tranche B-2 Term Facility” and the loans borrowed thereunder, the “Tranche B-2 Term Loans”) in an aggregate principal amount of $500 million (the “Incremental Tranche B-2 Term Loans”).

     

    Pursuant to the Ninth Amendment and the Credit Agreement, the Tranche B-2 Term Loans (including the Incremental Tranche B-2 Term Loans) shall be denominated in U.S. dollars and shall bear interest, at the Company’s option, based on (i) the Base Rate (as defined below) plus the Applicable Margin (as defined below), or (ii) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (“Term SOFR”) plus the Applicable Margin. The “Base Rate” with respect to the Tranche B-2 Term Facility is defined as the highest of (a) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 50 basis points, (b) the U.S. “prime rate” last quoted by The Wall Street Journal or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate established by the Board of Governors of the Federal Reserve System of the U.S. (the “Board”) in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the “bank prime loan” rate or, if such rate is no longer quoted therein, any similar rate quoted therein, or any similar release by the Board, in each case as determined by JPMorgan and (c) Term SOFR for an interest period of one month plus 100 basis points; provided that if the Base Rate is negative it shall be deemed to be zero. The “Applicable Margin” for the Tranche B-2 Term Facility is 175 basis points in the case of Term SOFR loans and 75 basis points in the case of Base Rate loans.

     

    The Company has used or will use the proceeds of the Incremental Tranche B-2 Term Loans (i) to repay a portion of its outstanding senior secured revolving loan facility terminating in November 2030, (ii) for the payment of fees, commissions and expenses in connection with the foregoing and for the Ninth Amendment itself and (iii) otherwise for general corporate purposes.

     

    The Company and its affiliates may from time to time engage certain of the lenders under the Credit Agreement to provide other banking, investment banking and financial services.

     

    The foregoing description of the Ninth Amendment does not purport to be complete and is qualified in its entirety by reference to the complete terms and conditions of the Ninth Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Ninth Amendment has been incorporated by reference herein to provide stockholders with information regarding its terms. It is not intended to provide any other information about the Company or the Company’s subsidiaries that are guarantors thereunder, or other subsidiaries and affiliates of the Company. For example, the Ninth Amendment contains representations and warranties that were made solely for the benefit of the other parties to the Ninth Amendment and should not be relied upon as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries.

     

    Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 4, 2026, DaVita Inc. (the “Company”) held its virtual 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Represented virtually or by proxy at the Annual Meeting were 59,865,902 shares of the Company's common stock, or approximately 91% of its outstanding shares of common stock as of April 9, 2026, the record date of the Annual Meeting. The proposals presented at the Annual Meeting are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 22, 2026. The vote results detailed below represent final results as certified by the Inspector of Elections.

     

    Proposal 1. Election of Directors.

     

    The Company’s stockholders elected the nine director nominees named below to the Company’s Board of Directors for a term expiring at the 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified. The voting results are as follows:

     

       For  Against  Abstain  Broker Non-Vote
    Pamela M. Arway  51,833,209  700,475  18,245  7,313,973
    Barbara J. Desoer  52,223,785  311,047  17,097  7,313,973
    Jason M. Hollar  52,234,585  299,851  17,493  7,313,973
    Gregory J. Moore, MD, PhD  52,463,031  71,921  16,977  7,313,973
    Dennis W. Pullin  52,460,686  54,311  36,932  7,313,973
    Javier J. Rodriguez  52,490,301  43,860  17,768  7,313,973
    Adam H. Schechter  52,355,165  179,111  17,653  7,313,973
    Wendy L. Schoppert  52,449,019  86,452  16,458  7,313,973
    Phyllis R. Yale  52,227,836  306,964  17,129  7,313,973

     

    Proposal 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm.

     

    The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results are as follows:

     

    For  Against  Abstain
    58,286,637  1,534,241  45,024

     

    Proposal 3. Advisory vote to approve named executive officer compensation.

     

    The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The voting results are as follows:

     

    For  Against  Abstain  Broker Non-Vote
    51,716,491  776,849  58,589  7,313,973

     

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    Number
    Description
    10.1 Ninth Amendment, dated as of June 8, 2026, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent and swingline lender (including a conformed copy of the Credit Agreement, reflecting all amendments through the Ninth Amendment, attached as Annex A thereto).
    104.0 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      DAVITA INC.
         
      By: /s/ Kathleen A. Waters
        Kathleen A. Waters
        Chief Legal and Public Affairs Officer

     

    Date: June 8, 2026

     

     

    Get the next $DVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    5/6/2026$220.00Hold → Buy
    Deutsche Bank
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    More analyst ratings

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DaVita upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded DaVita from Hold to Buy and set a new price target of $220.00

    5/6/26 7:31:43 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Sets Bold 2030 Community Care Commitments After Exceeding Prior Five-Year ESG Goals

    Kidney care leader launches its next chapter of measurable impact for patients, teammates, and communities.DENVER, May 18, 2026 /PRNewswire/ -- DaVita today announced its 2030 Community Care commitments, a new set of long-term goals, focused on improving patient outcomes, supporting the expansion of economic opportunity for teammates, and strengthening community and environmental resilience. The announcement follows the company achieving or exceeding the majority of its prior five-year environmental, social, and governance (ESG) goals, reinforcing DaVita's track record of turning ambition into measurable impact.Guided by its Trilogy of Care—Caring for Our Patients, Caring for Each Other and

    5/18/26 3:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 1st Quarter 2026 Results

    DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2026."DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc. "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception."Financial and operating highlights for the quarter and year ended March 31, 2026:Consolidated revenues were $3.416 billion.Operating income was $482 million.Diluted earnings per share from continuing operations was $2.87.Operating cash flow was $321 million and free cash flow was $140 m

    5/5/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Honeywell Announces Board of Directors for Honeywell Aerospace

    Directors bring compelling mix of aerospace and defense expertise, leadership experience, and financial and capital markets backgroundsHoneywell spin-off of Honeywell Aerospace expected to be completed on June 29, 2026Management will provide details on Honeywell Aerospace's value creation and financial outlook at an Investor Day on June 3, 2026 CHARLOTTE, N.C., April 28, 2026 /PRNewswire/ -- Honeywell (NASDAQ:HON) today announced the anticipated Board of Directors for Honeywell Aerospace, which will be one of the largest publicly listed pure-play aerospace and defense companies following its planned spin-off from Honeywell.

    4/28/26 7:00:00 AM ET
    $DVA
    $HON
    Misc Health and Biotechnology Services
    Health Care
    Aerospace
    Industrials

    $DVA
    SEC Filings

    View All

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    6/8/26 4:33:52 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 144 filed by DaVita Inc.

    144 - DAVITA INC. (0000927066) (Subject)

    5/6/26 4:03:39 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by DaVita Inc.

    10-Q - DAVITA INC. (0000927066) (Filer)

    5/5/26 5:03:02 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Yale Phyllis R gifted 5,038 shares, decreasing direct ownership by 35% to 9,525 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    5/28/26 4:22:54 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Pullin Dennis W was granted 250 shares, increasing direct ownership by 10% to 2,671 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    5/18/26 4:11:56 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Schoppert Wendy Lee was granted 250 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    5/18/26 4:11:45 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 1st Quarter 2026 Results

    DENVER, May 5, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2026."DaVita's foundation is clinical excellence, driven by operating rigor that produces durable results," said Javier Rodriguez, CEO of DaVita Inc. "We have consistently delivered exceptional clinical outcomes and strong financial performance, and this quarter is no exception."Financial and operating highlights for the quarter and year ended March 31, 2026:Consolidated revenues were $3.416 billion.Operating income was $482 million.Diluted earnings per share from continuing operations was $2.87.Operating cash flow was $321 million and free cash flow was $140 m

    5/5/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

    DENVER, April 20, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Tuesday, May 5, 2026, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day.This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, May 5, 2026 Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the co

    4/20/26 2:06:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 4th Quarter 2025 Results

    DENVER, Feb. 2, 2026 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter and year ended December 31, 2025. "Our strong platform delivered once again in 2025, providing high quality, innovative care to our patients and achieving the financial targets we set out at the beginning of the year despite a challenging environment," said Javier Rodriguez, CEO of DaVita. "Given our ongoing investments and process improvements, we are confident in our ability to continue to deliver both clinically and financially in 2026 and beyond." Financial and operating highlights for the quarter and year ended December 31, 2025: Consolidated revenues were $3.620 billion

    2/2/26 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care